报价延迟最少15分钟:2025/09/03 18:55 EDT
盘后时段
|
||||
|
0.6407 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.629
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.81/-0.09
|
|
企业价值
59.65M
|
| 资产负债 |
|
每股账面净值
-0.09
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/03 18:55 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |
